These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276 [TBL] [Abstract][Full Text] [Related]
10. Diffuse alveolar hemorrhage induced by everolimus. Vandewiele B; Vandecasteele SJ; Vanwalleghem L; De Vriese AS Chest; 2010 Feb; 137(2):456-9. PubMed ID: 20133293 [TBL] [Abstract][Full Text] [Related]
11. Causes of Hemoptysis in Renal Transplant Patients. Serifoglu I; Er Dedekarginoglu B; Ayvazoglu Soy EH; Ulubay G; Haberal M Exp Clin Transplant; 2018 Mar; 16 Suppl 1(Suppl 1):70-74. PubMed ID: 29527996 [TBL] [Abstract][Full Text] [Related]
12. Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Safdar N; Smith J; Knasinski V; Sherkow C; Herrforth C; Knechtle S; Andes D Diagn Microbiol Infect Dis; 2010 Jan; 66(1):7-15. PubMed ID: 19963164 [TBL] [Abstract][Full Text] [Related]
13. Fungal and mycobacterial infections after Campath (alemtuzumab) induction for renal transplantation. Walsh R; Ortiz J; Foster P; Palma-Vargas J; Rosenblatt S; Wright F Transpl Infect Dis; 2008 Jul; 10(4):236-9. PubMed ID: 18086280 [TBL] [Abstract][Full Text] [Related]
14. A case of lung injury resembling diffuse pulmonary hemorrhage after the first administration of alemtuzumab in a patient with multiple sclerosis. Role of the HRCT. Cipolla G; Relo R; Pasciuta E; Catalano D; Lo Bello F; Coppolino I; Ruggeri P; Proietto A; Buccafusca M; Cutroneo PM; Trifirò G; Caramori G Monaldi Arch Chest Dis; 2020 Jul; 90(3):. PubMed ID: 32702962 [TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326 [TBL] [Abstract][Full Text] [Related]
17. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781 [TBL] [Abstract][Full Text] [Related]
18. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation. Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701 [TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab. Song WK; Min YH; Kim YR; Lee SC Ophthalmology; 2008 Oct; 115(10):1766-70. PubMed ID: 18562004 [TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab induction in kidney transplantation. Huang E; Cho YW; Shah T; Peng A; Hayashi R; Bunnapradist S Clin Transpl; 2005; ():343-54. PubMed ID: 17424750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]